BriaCell Therapeutics (TSX.V: BCT) (OTCQB: BCTXF), an
immuno-oncology focused biotechnology company with a proprietary targeted
immunotherapy technology, today announced that it has achieved proof of concept
in the Phase IIa study of its lead clinical candidate, Bria-IMT™, in advanced
breast cancer. The data demonstrates promising anti-tumor activity of Bria-IMT™
in heavily pre-treated advanced breast cancer patients. The company is focusing
on the combination study of the candidate with pembrolizumab (Keytruda®;
manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy®; manufactured by
Bristol-Myers Squibb Company) to boost the anti-tumor activity of Bria-IMT™.
Given the conclusive findings of the first 20 patients in the Phase IIa Bria-IMT™
monotherapy study, enrollment for the study is now closed. The company has
initiated a combination study of Bria-IMT™ for which enrollment is now open.
“Bria-IMT™ appears to be most effective in patients who match with Bria-IMT™ at
2 HLA loci (types) further supporting BriaCell’s HLA Matching Hypothesis, and
the development of Bria-OTS™ to cover 90% of the patient population. We are
delighted with these positive clinical findings that confirm our HLA Matching
Hypothesis in the Phase I/IIa trial in advanced breast cancer showing
significant tumor shrinkage without serious side effects,” BriaCell
Therapeutics president and CEO Dr. Bill Williams stated in the news release.
“We believe that combination studies with immune checkpoint inhibitors should
create even more potent anti-cancer immune responses, leading to our strategy
of combination studies of Bria-IMT™ with Keytruda® or Yervoy®.”
BriaCell is hosting a webcast at 4:15pm ET to discuss the
results. The company’s president and CEO Dr. Bill Williams will present
Bria-IMT™’s proof of concept clinical data during the webcast. To join the
webcast, call the toll-free line in North America at 1-855-327-6837; the
Toronto line at 1-416-915-3239; the Montreal line at 1-514-375-0364; or the
Vancouver line at 1-778-327-3988. To listen to a replay of the webcast, call
the toll-free line in North America at 1-844-512-2921.
To view the slide presentation to follow along with the
webcast, visit http://ibn.fm/Qt2aa
To view the full press release, visit http://ibn.fm/QQ442
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company
developing targeted and safe approaches for the management of cancer. BriaCell
is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, its lead
candidate, in a combination study with pembrolizumab [Keytruda®; manufactured
by Merck & Co., Inc.] or ipilimumab [Yervoy®; manufactured by Bristol-Myers
Squibb Company]. The combination study is listed in ClinicalTrials.gov as
NCT03328026. BriaCell is developing Bria-OTS™, an off-the-shelf personalized
immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments
are personalized to match the patient without the need for personalized
manufacturing. Bria-OTS™, which is expected to cover over 90% of the patient
population, is designed to produce a potent and selective immune response
against the cancer of each patient while eliminating the time, expense, and
complex manufacturing logistics associated with other personalized
immunotherapies. For more information, visit the company’s website at www.BriaCell.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment